SparingVision is a biotechnology company developing genomic medicines for the treatment of blinding inherited retinal diseases.
SparingVision has raised $74.9M in total funding. The most recent round was Series B. The last funding was announced in September 2022.
SparingVision's investors include Bpifrance, Jeito Capital, 4BIO Capital, Ysios Capital, Intellia Therapeutics.
SparingVision is headquartered in Paris, France.
SparingVision is a biotechnology company developing genomic medicines for the treatment of blinding inherited retinal diseases.
SparingVision is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"SparingVision — Funding & Investors." VCBacked, September 14, 2022, https://www.vcbacked.co/company/sparingvision. Accessed August 13, 2026.
VCBacked. (2022). SparingVision — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/sparingvision
{{cite web |title=SparingVision — Funding & Investors |url=https://www.vcbacked.co/company/sparingvision |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated